Ropivacaine synergizes with sorafenib to induce apoptosis of hepatocellular carcinoma cells via the IL‐6/STAT3 pathway

Cancer Science, Journal Year: 2024, Volume and Issue: 115(9), P. 2923 - 2930

Published: July 16, 2024

Abstract The development of resistance in hepatocellular carcinoma (HCC) cells limits the effectiveness sorafenib, but combination therapy with other drugs may have a positive effect. However, effect ropivacaine combined sorafenib on treatment HCC and its potential regulatory mechanisms remain unclear. proliferation apoptosis treated ropivacaine, plus were analyzed by cell‐counting kit 8 flow cytometry. protein levels measured Western blot. antitumor their was verified tumor xenograft model. Ropivacaine markedly impeded viability concentration‐dependent manner. Compared or alone, cell proliferation, facilitated apoptosis, enhanced cleaved caspase‐3, caspase‐9, cyclin D1 expression, while it reduced IL‐6 p‐STAT3 expression inhibited growth vivo. Importantly, activation IL‐6/STAT3 pathway could reverse repressive stimulative effects cells. In summary, synergistically induces sorafenib‐stimulated via pathway. is drug for when sorafenib.

Language: Английский

Innovative applications and research progress of hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma

World Journal of Gastrointestinal Oncology, Journal Year: 2025, Volume and Issue: 17(2)

Published: Jan. 18, 2025

This article provides an in-depth analysis of the study conducted by Wang et al, which explores hepatic arterial infusion chemotherapy and its synergistic strategies in managing advanced hepatocellular carcinoma (HCC). HCC ranks as fourth most common cause cancer-related mortality globally is frequently associated with portal vein tumor thrombus (PVTT). The approach to HCC, particularly when PVTT present, diverges markedly between Eastern Western practices. These differences are rooted variations epidemiology, etiology, pathology, comorbidities, prognosis. paper delves into diagnosis, classification, treatment for PVTT, well evolving role advancements therapeutic landscape HCC.

Language: Английский

VCP Promotes Cholangiocarcinoma Development by Mediating BAP1 Ubiquitination‐Dependent Degradation

Cancer Science, Journal Year: 2025, Volume and Issue: unknown

Published: March 23, 2025

ABSTRACT Cholangiocarcinoma (CCA), recognized for its high malignancy, has been an enormous challenge due to lacking effective treatment therapy over the past decades. Recently, targeted therapies, such as Pemigatinib and Ivosidenib, have provided new options patients carrying fibroblast growth factor receptor (FGFR) isocitrate dehydrogenase 1/2 (IDH1/2) mutations, but only ~30% of harbor these mutants; it is urgent explore novel targets therapeutic therapies. The frequent downregulation BAP1 observed in CCA, low expression closely related poor prognosis CCA. However, there are no interventions re‐activate protein; blocking degradation may provide a feasible strategy BAP1‐downregulation CCA treatment. In this study, we demonstrated tumor‐suppressive roles identified VCP functions key upstream regulator mediated by protein homeostasis. Mechanistically, binds promotes latter's ubiquitination via ubiquitin‐proteasome pathway, thus promoting cell proliferation inhibiting apoptosis. Moreover, found that inhibitors inhibited promoted apoptosis degradation. Collectively, our findings not mechanism underlying aberrant also verified anti‐tumor effect offering target

Language: Английский